CRANFORD, N.J., June 13,
2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc.
("Citius" or the "Company") (Nasdaq: CTXR), a late-stage
biopharmaceutical company dedicated to the development and
commercialization of first-in-class critical care products, today
announced that Chairman and CEO Leonard
Mazur will participate in a fireside chat with Senior
Biotech Research Analyst, Michael
Okunewitch, at Maxim Group's Virtual Healthcare Conference
on June 21, 2023.
Conference Details:
Date:
|
Wednesday, June
21, 2023
|
Time:
|
1:00 PM ET
|
Location:
|
Virtual
|
Live
presentation:
|
Viewers must
register for the conference
to view the live presentation.
|
|
|
About Citius Pharmaceuticals, Inc.
Citius is a late-stage biopharmaceutical company dedicated to
the development and commercialization of first-in-class critical
care products, with a focus on oncology, anti-infectives in adjunct
cancer care, unique prescription products, and stem cell therapies.
The Company's diversified pipeline includes two late-stage product
candidates, Mino-Lok®, an antibiotic lock solution for the
treatment of patients with catheter-related bloodstream infections,
which is currently enrolling patients in a Phase 3 Pivotal
superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy
for an initial indication in CTCL, for which a BLA is under review
by the FDA. Mino-Lok® was granted Fast Track designation by
the FDA. I/ONTAK has received orphan drug designation by the FDA
for the treatment of CTCL and PTCL. At the end of March 2023, Citius completed enrollment in its
Phase 2b trial of CITI-002, a topical
formulation for the relief of hemorrhoids. For more information,
please visit www.citiuspharma.com.
Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113
View original content to download
multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-participate-in-maxim-groups-virtual-healthcare-conference-on-june-21-2023-301849096.html
SOURCE Citius Pharmaceuticals, Inc.